Alberto Severini on behalf of the N.E.W working group

Slides:

Advertisements

Similar presentations

Monitoring the impact of vaccination on rubella and CRS Susan E. Reef, MD 11 th Annual Meeting The Measles and Rubella Initiative Sept. 19, 2012.

Advertisements

Travel Medicine In Alberta: Can Public Health Do more? Silvina Mema 1, Judy MacDonald 2, Rudy Zimmer 3, David Strong 2, Lynn McIntyre 4 1 Public Health.

A global partnership to stop measles & rubella Competent and Sustainable Global Laboratory Surveillance for Measles and Rubella is Provided by the WHO.

Monitoring progress towards the coverage and disease incidence targets GLOBAL MEASLES AND RUBELLA MANAGEMENT MEETING March 2011 Geneva, Switzerland.

Measles and Rubella Elimination in the WHO European Region: Update on Progress & Challenges Global Measles and Rubella Management Meeting March 2011.

Innovation and new Technologies for measles eradication Dr. David Brown Virus Reference Department HPA Microbiology services Global Measles and Rubella.

Role of the laboratory in disease surveillance

A global partnership to stop measles & rubella The Measles & Rubella Initiative: Preparing for the Next Decade Lisa Cairns, MD, MPH Sept 18, 2012 Washington,

The Laboratory Response Network

Proceedings of the SAGE Working Group on Rubella Vaccines Susan E. Reef, MD Global Measles and Rubella Management Meeting March 15, 2011.

1 Webinar on: Establishing a Fully Integrated National Food Safety System with Strengthened Inspection, Laboratory and Response Capacity Sponsored by Partnership.

PROJECT DATECLIENT October 16, 2014 ALABAMA SCIENCE TEACHERS STEM-IQ GEARSEF Orientation.

Laboratory Training for Field Epidemiologists Strengthening Laboratory and Epidemiology Collaboration Introduction May 2007.

Reaching the 2010 Measles Mortality Reduction Goal-can SEARO get there? Meeting of the Partners for Measles Advocacy Washington DC, September 2008.

Progress towards Sustainable Measles Mortality Reduction South-East Asia Region Jayantha Liyanage Medical Officer- EPI Immunization and Vaccine Development.

Outline Background Objectives and activities GPEI assets

California Statewide Prevention and Early Intervention (PEI) Projects Overview May 20, 2010.

ISO Sampling Agreement Requirements and National Sampling Plan Guy F. Delius CSO FDA Tim McGrath Acting Deputy Director ORS-FDA March 10, :15-1:45.

AFR Measles-Rubella TAG Meeting, |1 | The Performance of the Regional Laboratory Network Nairobi, 2-3 June 2015 The Performance of the Regional.

Coalition 101. RESPECT AND VALUE “The group respects my opinion and provides positive ways for me to contribute.” EFFICIENCY AND EFFECTIVENESS “The roles.

Dr. David Mowat June 22, 2005 Federal, Provincial & Local Roles Surveillance of Risk Factors and Determinants of Chronic Diseases.

Epidemiology of Vaccine Preventable diseases in Iran

Palestine Bahrain Global Measles and Rubella Management Meeting Boubker Naouri March, 2011 Geneva, WHO HQ.

8 th Global Measles and Rubella LabNet Meeting, Sept 2010 Key Recommendations GLOBAL MEASLES AND RUBELLA MANAGEMENT MEETING March 2011 Salle B, WHO.

1 1 Bose: SEAR Highlights and Priorities Global Measles & Rubella Management Meeting Geneva, March 2011 Accelerated Measles Control: Highlights and.

World Health Organization Eastern Mediterranean Region.

David Featherstone EPI / IVB WHO/HQ Measles Partners Meeting September 2008 Washington Global Measles Rubella Laboratory Network: Update.

Laboratory Results and Operations in WHO Phase 6 Dr. Attaporn Taweetungtragoon CYBELES Phnom Penh, Cambodia October 12-15, 2009.

1 DEWG meeting October 2009 Human Resource Development for TB Control (HRD-TB) Sub Group within the DEWG of the Stop TB Partnership. Wanda Walton.

Update on Progress toward Measles Situation in EMR September 2008 Dr B. Naouri VPI/DCD/EMRO.

2015 Measles & Rubella Initiative Annual Partners Meeting, Human & Financial Costs of Measles and Rubella, 15 September 2015, Washington, DC Achieving.

A global partnership to stop measles & rubella 1 Measles & Rubella Initiative --Who We Are-- Stephen Cochi, MD, MPH Global Immunization Division Centers.

Sustaining the gains and reaching milestones on the way towards elimination of measles and rubella 15 September 2015 Dr Peter Strebel, WHO, IVB/EPI.

Infection Control Road Show 2011 Outbreak Management.

Lesson 3 Page 1 of 24 Lesson 3 Considerations in Planning Public Health Surveillance.

Accelerating Progress towards Measles and Rubella Elimination, June 2016, Hotel Royal, Geneva National Center for Immunization & Respiratory Diseases.

Updates from the Regional Measles and Rubella Laboratory Network. Accelerating Progress towards Measles and rubella Elimination Gloria Rey-Benito PAHO,

Accelerating progress towards MR elimination, |1 | Update from Regional Measles & Rubella Laboratory Network, African Region Hotel Royal, Geneva,

Influenza Virologic Surveillance and Vaccine Strain Selection Xiyan Xu MD Deputy Director WHO Collaborating Center for Surveillance, Epidemiology and Control.

Session 3: Molecular Epidemiology Introduction

TB Genotyping and Whole Genome Sequencing in California

Next generation and Extended sequencing Working group (NEW) for measles and rubella and the NEW working group Accelerating Progress towards Measles and.

Whole Genome sequencing for measles ; A case study in Brazil

Status of the WHO measles and rubella laboratory manual

Vaccine specific RT-PCR for measles (MeVA)

Evolution of rubella viruses following long term endemic circulation

Disappearance of measles genotypes

Use of next generation Sequencing (NGS) at a National Reference Laboratory, Denmark 2015/16 Authors: Thea Kølsen Fischer, Ramona Trebbien, Jannik Fonager,

Molecular EQA for GMRLN: Year Two

53 Member States >900 million inhabitants WHO European Region

World Health Organization

MeaNS, RubeNS and a global update

reporting rate of discarded cases* per 100'000 population**

ISARIC – INTERNATIONAL SEVERE ACUTE RESPIRATORY INFECTION CONSORTIUM

ILAC Marketing & Communications

Accelerating Progress Towards Measles and Rubella

World Health Organization

World Health Organization

Recap of the Midterm Review Recommendations

Molecular surveillance of measles and rubella in the WHO European Region: new challenges in the elimination phase S. Santibanez, J.M. Hübschen, M.C.

Session 1: New Opportunities and New Direction

23 November, 2018 Update on measles & rubella surveillance in the WHO African Region – progress and challenges Dr Richard Luce WHO/IST-Central 5th African.

Public Health Interventions

J. M. Hübschen, S. M. Bork, K. E. Brown, A. Mankertz, S. Santibanez, M

Utility of NIST Whole-Genome Reference Materials for the Technical Validation of a Multigene Next-Generation Sequencing Test Bennett O.V. Shum, Ilya.

Response Teams – Planning and Preparation

Supplemental Figure 1. total n=862

Comprehensive M&E Systems

National Immunization Conference, Dallas, TX

Presentation transcript:

Next generation and Extended sequencing Working group (NEW) for measles and rubella Alberto Severini on behalf of the N.E.W working group National Microbiology Laboratory Public Health Agency of Canada alberto.severini@phac-aspc.gc.ca Accelerating Progress towards Measles and Rubella Elimination, WHO Geneva, June 21-23, 2016

Background The current genotyping approaches (N450 and the H gene for measles) is adequate for routine genotyping However, as we are getting closer to the elimination of measles and rubella the diversity of their genomes diminishes Standardised genotyping targets are often insufficient to distinguish repeated importations from local transmission We need to develop an extended, practical, genotyping target to help document elimination and to rule out endemic transmission

The Next generation and Extended sequencing Working group (NEW) for measles and rubella NEW was created in response to discussions on the need for more discriminating methods for the genotyping of measles and rubella. The creation of NEW was one of the recommendation stemming form the 12th Global LabNet meeting in Istanbul.

Summary of NEW’s objectives (formal terms of reference available) To evaluate and share methods and applications for whole genome sequencing (WGS), next generation sequencing (NGS) extended genome sequencing for measles and rubella To evaluate the utility of these methods for molecular surveillance To establish a catalogue of WGS and extended sequencing collecting data on the rate of measles and rubella genomic change during outbreaks defining the variability of measles and rubella genomes.

To report to and advise the WHO measles and rubella laboratory network. NEW met in Berlin on March 16-17, 2016 We developed a set of recommendations for GRMLN We developed a set of standards for obtaining and depositing measles sequences

Utility Extended and WGS are not meant to replace standard genotyping by N-450 for measles and 739 from the E1 gene for rubella WGS or sequencing of the MF-NCR region of measles has proven its utility in low incidence setting, when standard genotyping fails Extensive and uniform sampling of outbreaks, plus a prior knowledge of related sequences, are needed to make the results interpretable It is recommended to obtain as many measles and rubella genomic sequences as possible to develop a database that will aid in outbreak investigations

Collaborations and data collection It is recommended to obtain as many measles and rubella genomic sequences as possible to develop a database that will aid in outbreak investigations. NLs are encouraged to collect and store specimens (suited for culture isolation, if possible) for extended sequencing and to collaborate with GSLs and RRLs that have capacity for whole genome and/or extended sequencing. MeaNS and RubeNS eventually be able accept measles and rubella whole genome sequences and measles MF-NCR sequences.

Standards (in brief) At this time, there are no recommendations regarding standard protocols for obtaining sequences. WGS-t - Whole genome excluding termini MF-NCR sequence – From the stop codon of the M gene to the start codon of the F gene. Next generation sequencing coverage minimum 10 reads Sanger sequencing minimum bidirectional No unsequenced bases

Measles genome WHO genotyping N target 450 nt MF-NCR target 1018 nt Alternate genotyping target: H ORF, 1854 nt Moss & Griffin, 2006 WGS-t 15,875 nt

WGS resolves the chains of transmission Whole genome

D8 (Taunton) imported from the Netherlands in 2014 13-0338) MVs/Ontario.CAN/30.13 13-0340) MVs/British Columbia.CAN/31.13 14-0345) MVs/British Columbia.CAN/11.14/3 14-0407) MVs/Alberta.CAN/12.14/2 13-0599) MVs/Alberta.CAN/44.13/5 14-0436) MVs/British Columbia.CAN/13.14/3 14-0384) MVs/British Columbia.CAN/12.14/2 14-0298) MVs/British Columbia.CAN/09.14/4 13-0597) MVs/Alberta.CAN/44.13/3 14-0435) MVs/British Columbia.CAN/13.14/2 14-0349) MVs/British Columbia.CAN/11.14/7 14-0275) MVs/British Columbia.CAN/09.14/3 13-0596) MVs/Alberta.CAN/44.13/2 14-0433) MVs/British Columbia.CAN/13.14 14-0348) MVs/British Columbia.CAN/11.14/6 14-0273) MVs/British Columbia.CAN/09.14/2 13-0578) MVs/Alberta.CAN/44.13 14-0347) MVs/British Columbia.CAN/11.14/5 14-0271) MVs/British Columbia.CAN/09.14 13-0554) MVs/Alberta.CAN/43.1 14-0573) MVs/Saskatchewan.CAN/16.14/4 14-0391) MVs/British Columbia.CAN/12.14/8 14-0346) MVs/British Columbia.CAN/11.14/4 14-0002) MVs/Alberta.CAN/43.13/3 13-0528) MVs/Alberta.CAN/42.13/2 14-0560) MVs/Saskatchewan.CAN/16.14/3 14-0389) MVs/British Columbia.CAN/12.14/7 14-0001) MVs/Alberta.CAN/46.13/3 13-0527) MVs/Alberta.CAN/42.13 14-0559) MVs/Saskatchewan.CAN/17.14 14-0388) MVs/British Columbia.CAN/12.14/6 14-0343) MVs/British Columbia.CAN/11.14/2 13-0643) MVs/British Columbia.CAN/46.13 13-0498) MVs/Alberta.CAN/41.13 14-0558) MVs/Saskatchewan.CAN/16.14/2 14-0387) MVs/British Columbia.CAN/12.14/5 14-0311) MVs/British Columbia.CAN/11.14 13-0601) MVs/Alberta.CAN/44.13/7 14-0557) MVs/Saskatchewan.CAN/16.14 14-0386) MVs/British Columbia.CAN/12.14/4 14-0309) MVs/British Columbia.CAN/10.14/6 13-0600) MVs/Alberta.CAN/44.13/6 14-0437) MVs/British Columbia.CAN/13.14/4 14-0385) MVs/British Columbia.CAN/12.14/3 14-0301) MVs/British Columbia.CAN/10.14/3 D8 MVi/Manchester.GBR/30.94 U29285 14-0599) MVs/Alberta.CAN/16.14/5 99 2 13-0554)MVs/AB.CAN/43.13 13-0596)MVs/AB.CAN/44.13/2 13-0597)MVs/AB.CAN/44.13/3 13-0599)MVs/AB.CAN/44.13/5 13-0339)MVs/ON.CAN/30.13 13-0600)MVs/AB.CAN/44.13/6 13-0601)MVs/AB.CAN/44.13/7 13-0498)MVs/AB.CAN/41.13 13-0527)MVs/AB.CAN/42.13 14-0001)MVs/AB.CAN/46.13/3 13-0528)MVs/AB.CAN/42.13/2 13-0578)MVs/AB.CAN/44.13 14-0002)MVs/AB.CAN/43.13/3 13-0340)MVs/BC.CAN/31.13 13-0643)MVs/BC.CAN/46.13 JN635407.1 MVi/Texas.USA/4.07 14-0599)MVs/AB.CAN/16.14/5 JN635404.1 MVi/Virginia.USA/15.09 100 5 14-0492)MVs/BC.CAN/13.14/5 14-0557)MVs/SK.CAN/16.14 14-0558)MVs/SK.CAN/16.14/2 14-0309)MVs/BC.CAN/10.14/6 14-0560)MVs/SK.CAN/16.14/3 14-0559)MVs/SK.CAN/17.14 14-0573)MVs/SK.CAN/16.14/4 14-0343)MVs/BC.CAN/11.14/2 14-0388)MVs/BC.CAN/12.14/6 14-0391)MVS/BC.CAN/12.14/8 14-0298)MVs/BC.CAN/09.14/4 14-0435)MVs/BC.CAN/13.14/2 14-0349)MVs/BC.CAN/11.14/7 14-0275)MVs/BC.CAN/09.14/3 14-0433)MVs/BC.CAN/13.14 14-0348)MVs/BC.CAN/11.14/6 14-0273)MVs/BC.CAN/09.14/2 14-0407)MVs/AB.CAN/12.14/2 14-0347)MVs/BC.CAN/11.14/5 14-0271)MVs/BC.CAN/09.14 14-0346)MVs/BC.CAN/11.14/4 14-0390)MVs/BC.CAN/12.14/7 14-0345)MVs/BC.CAN/11.14/3 14-0387)MVs/BC.CAN/12.14/5 14-0311)MVs/BC.CAN/11.14 14-0386)MVs/BC.CAN/12.14/4 14-0437)MVs/BC.CAN/13.14/4 14-0385)MVs/BC.CAN/12.14/3 14-0301)MVs/BC.CAN/10.14/3 14-0436)MVs/BC.CAN/13.14/3 14-0384)MVs/BC.CAN/12.14/2 58 66 36 52 H gene MF UTR EWGNGSWG

NEW current membership WHO Mick Mulders US CDC Bettina Benkamp Min-hsin Chen Joe Icenogle Paul Rota Public Health England Kevin Brown Ana Penedos Luxemburg Institute of Health Judith Huebschen Claude Muller RKI Germany Annette Mankertz Sabine Santibanez GIE - Russian Federation Sergey Shulga NML Canada Joanne Hiebert Alberto Severini

New members welcome Laboratories with an interest in extended sequencing should consider joining NEW Next NEW meeting will be on Friday, June 24 at !3:30 at HQ Rm M105 (open to all plenary meeting participants)